ArticlePloS one2026
Prevalence and risk factors for nephrolithiasis in adults with cystic fibrosis: A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalcium oxalate nephrolithiasis is more common in persons living with cystic fibrosis (PwCF) than in the general population. A primary risk factor is exocrine pancreatic insufficiency (EPI) causing enteral hyperoxaluria. However, the relationship between nephrolithiasis and degree of EPI control has not been assessed.
methodsA retrospective cohort study was conducted including all PwCF seen at our institution from 2018 to 2023 (n = 332). Collected data included socio-demographics, Charlson comorbidity index, EPI control status adjudicated by treating clinicians (classified as controlled, uncontrolled, or unknown), and nephrolithiasis events, which were classified as symptomatic or asymptomatic when nephrolithiasis were discovered incidentally on imaging. Incidence and lifetime prevalence rates were calculated for the entire sample and according to EPI control. A multivariable logistic regression model for the outcome of nephrolithiasis was performed using likelihood-ratio-based backwards stepwise selection.
resultsThe cumulative lifetime prevalence of any nephrolithiasis event in our study population was 32%. The lifetime prevalence was higher in EPI (32%) than no EPI (24%), but there was no significant difference in prevalence according to EPI control status. The multivariable model identified that small bowel resection (odds ratio [OR] 3.0, 95% confidence interval (CI) 1.0-9.0)), alcohol use (OR 1.7, 95% CI 1.0-2.9), and decreased BMI (OR 0.9, 95% CI 0.9-1.0) were independently associated with nephrolithiasis. Among 105 individuals with nephrolithiasis, 51% (n = 54) had recurrent events. An invasive procedure was required by 10% (n = 3) with a single nephrolithiasis event and was required by 61% (n = 33) with recurrent nephrolithiasis.
conclusionsNephrolithiasis events are common in PwCF. We observed an increased prevalence among PwCF with EPI, but did not observe a difference based on the degree of EPI control although this may be limited by reliance on clinician assessment of EPI control rather than a more objective measure. Prospective investigation with detailed assessment of risk factors including dietary habits and EPI control is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.